BioPivot places American compounding near the center of its weight-management offer. Its public pages also identify separate clinical and fulfillment contacts, giving readers more to follow than a general domestic-shipping badge. The useful question is which organization handles each step of the proposed prescription, and what documentation supports that particular role.
We checked the homepage, tirzepatide description and cancellation policy on October 15, 2026. This review follows public service claims and identifies a material fee inconsistency. It does not report a completed consultation, a pharmacy inspection or verified patient results. American Made GLP-1’s separate CoreAge commercial placement is disclosed below.
Trace the care and fulfillment organizations separately
BioPivot’s homepage FAQ names Elite Care Health for clinical care and Rx Ave Health for pharmacy and prescription fulfillment, with contact details for each. Its tirzepatide page repeats those contacts and describes an independent physician group. These names help a reader ask a specific question; they do not independently verify every professional license or identify the dispensing pharmacy for a particular order.
Retain the actual prescriber and pharmacy names when a plan is proposed. Our US-origin guide distinguishes the platform, clinician, ingredient source, preparing pharmacy and shipping location. A named fulfillment contact may be useful without answering all five questions.
US preparation does not establish every ingredient’s origin
The tirzepatide page says partner pharmacies in the United States prepare the protocols. It describes discreet, temperature-controlled delivery and structured shipment timing. We did not find a public manufacturing chain or batch-specific document establishing where every ingredient originated. We therefore treat domestic preparation and delivery as the company’s claims, without expanding them into a complete country-of-origin certification.
The actual label, pharmacy record and preparation details matter more than an American address alone. If ingredient origin is part of a buying decision, ask for documentation specific to that ingredient and order. A shipping origin and a manufacturing origin can describe different stages.
Compounding and approval remain different questions
BioPivot’s FAQ explicitly says its compounded medicines are not FDA-approved. FDA’s GLP-1 guidance explains the absence of premarket review for compounded products and the role of patient needs that cannot be met by an approved medicine. Domestic compounding does not change that distinction.
The tirzepatide description also connects a dual-receptor mechanism with accelerated results and trial outcomes. We did not identify a linked trial of the exact BioPivot preparation establishing those program claims. Evidence for an approved product cannot simply be transferred to a different compounded formula. The formulation guide provides related questions about identifying the medicine before comparing results.
The consultation-fee statements conflict
The homepage advertises a first review at no charge and says an applicant pays nothing if not approved. Its June 2026 cancellation policy instead says an applicant who is declined receives the membership payment back minus a $59 doctor consultation fee. Those descriptions cannot both determine the same declined application without further explanation.
Obtain the terms for the selected offer before submitting payment or intake. We have not resolved the conflict by choosing whichever statement is more favorable. The policy also distinguishes cancellation before clinical review from cancellation after a prescription, so timing affects the company’s stated refund treatment.
A starting monthly figure does not reveal the total commitment
The homepage advertises plans starting at $149 per month, confirmed after provider review. The cancellation policy describes a three-month membership, continued access through the paid term after cancellation and restrictions once medication has shipped. The starting figure is not a verified total for a selected tirzepatide plan.
Ask for the amount due now, paid term, renewal date, pharmacy-processing cutoff and refund conditions in one written agreement. We did not enter checkout or test refund processing. The detailed policy provides a place to start, while the inconsistent declined-applicant charge remains a specific issue to reconcile.
The care promise needs an assigned clinician
The program description includes physician review, secure messaging and scheduled check-ins. The homepage says applicants generally hear back within 48 hours, while its FAQ allows for additional information, labwork or a consultation depending on the assessment. These are advertised arrangements rather than measured service performance.
BioPivot’s public record identifies the intended care model and US-compounding claim, but the individual prescription, pharmacy assignment and accepted payment terms remain essential. Compare those records with the MANÜ review, which follows a different domestic-pharmacy claim, and the review directory. A named partner or an origin slogan cannot establish individual suitability or a guaranteed outcome.
Sources and review method
Public documents checked 2026-10-15. Provider pages support attributed service and price descriptions; FDA material supplies regulatory context. We did not conduct a purchase, patient study or professional credential audit. Offers may change.